Norverapamil (hydrochloride) (Standard)

Norverapamil (hydrochloride) (Standard) is the analytical standard of Norverapamil (hydrochloride) . This product is intended for research and analytical applications. Norverapamil hydrochloride ((±) -Norverapamil hydrochloride), an N-demethylated metabolite of Verapamil, is a L-type calcium channel blocker and a P-glycoprotein (P-gp) function inhibitor[1][2].

Product Specifications

CAS Number

[67812-42-4]

Product Name Alternative

(±) -Norverapamil (hydrochloride) (Standard) ; D591 (hydrochloride) (Standard)

UNSPSC

12352005

Target

Calcium Channel; Drug Metabolite; P-glycoprotein; Reference Standards

Related Pathways

Membrane Transporter/Ion Channel; Metabolic Enzyme/Protease; Neuronal Signaling; Others

Field of Research

Cardiovascular Disease

Smiles

N#CC(C(C)C)(CCCNCCC1=CC=C(OC)C(OC)=C1)C2=CC=C(OC)C(OC)=C2.[H]Cl

Molecular Formula

C26H37ClN2O4

Molecular Weight

477.04

References & Citations

[1]Adams KN, et al. Verapamil, and its metabolite norverapamil, inhibit macrophage-induced, bacterial efflux pump-mediated tolerance to multiple anti-tubercular drugs. J Infect Dis. 2014 Aug 1;210 (3) :456-66.|[2]Wang J et al. A semi-physiologically-based pharmacokinetic model characterizing mechanism-based auto-inhibition to predict stereoselective pharmacokinetics of verapamil and its metabolite norverapamil in human. Eur J Pharm Sci. 2013 Nov 20;50 (3-4) :290-302.|[3]Choi DH, et al. Effects of simvastatin on the pharmacokinetics of verapamil and its main metabolite, norverapamil, in rats. Eur J Drug Metab Pharmacokinet. 2009 Jul-Sep;34 (3-4) :163-8.|[4]Pauli-Magnus C, et al. Characterization of the major metabolites of verapamil as substrates and inhibitors of P-glycoprotein. J Pharmacol Exp Ther. 2000 May;293 (2) :376-82.